Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Stomach Neoplasms 8Carcinoma, Hepatocellular 8Neoplasm Metastasis 7Triple Negative Breast Neoplasms 6Rectal Neoplasms 6Nasopharyngeal Carcinoma 6Melanoma 6Lymphoma, Extranodal NK-T-Cell 6Locally Advanced Rectal Cancer 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Cholangiocarcinoma 3Thyroid Neoplasms 2Nasopharyngeal Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Kidney Neoplasms 2Hemangiosarcoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Adenocarcinoma Of Esophagus 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

Etoposide 5Doxorubicin 5Vincristine 4Ifosfamide 4Cyclophosphamide 4Filgrastim 3fludarabine phosphate 2Thiotepa 2Tacrolimus 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Injections 2Cyclosporine 2Carboplatin 2thymoglobulin 1temsirolimus 1spartalizumab 1pazopanib 1pasireotide 1exatecan 1Topotecan 1Temozolomide 1Taxes 1Surgical Procedures, Operative 1Sunitinib 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Desmoplastic Small Round Cell Tumor × spartalizumab × Clear all
NCT02982486 2017-11-01

A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma

Assaf-Harofeh Medical Center

Phase 2 Unknown
60 enrolled
GastrointestinalSarcoma

Bone Neoplasms, Chondrosarcoma, Sarcoma, Osteosarcoma, Gastrointestinal Stromal Tumors, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡